304 related articles for article (PubMed ID: 27908681)
1. Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer.
Soria F; Moschini M; Abufaraj M; Wirth GJ; Foerster B; Gust KM; Özsoy M; Briganti A; Gontero P; Mathieu R; Rouprêt M; Karakiewicz PI; Shariat SF
Urol Oncol; 2017 Mar; 35(3):113.e9-113.e14. PubMed ID: 27908681
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer.
Kimura S; D' Andrea D; Soria F; Foerster B; Abufaraj M; Vartolomei MD; Iwata T; Karakiewicz PI; Rink M; Gust KM; Egawa S; Shariat SF
Urol Oncol; 2019 Mar; 37(3):179.e19-179.e28. PubMed ID: 30580906
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer.
Kimura S; Soria F; D'Andrea D; Foerster B; Abufaraj M; Vartolomei MD; Karakiewicz PI; Mathieu R; Moschini M; Rink M; Egawa S; Shariat SF; Gust KM
Clin Genitourin Cancer; 2018 Dec; 16(6):e1123-e1132. PubMed ID: 30061034
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer.
Abufaraj M; Shariat SF; Haitel A; Moschini M; Foerster B; Chłosta P; Gust K; Babjuk M; Briganti A; Karakiewicz PI; Albrecht W
Urol Oncol; 2017 May; 35(5):264-271. PubMed ID: 28214283
[TBL] [Abstract][Full Text] [Related]
5. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
[TBL] [Abstract][Full Text] [Related]
6. Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer.
Vartolomei MD; Ferro M; Cantiello F; Lucarelli G; Di Stasi S; Hurle R; Guazzoni G; Busetto GM; De Berardinis E; Damiano R; Perdona S; Verze P; La Rocca R; Borghesi M; Schiavina R; Brunocilla E; Almeida GL; Bove P; Lima E; Grimaldi G; Autorino R; Crisan N; Abu Farhan AR; Battaglia M; Serretta V; Russo GI; Morgia G; Terracciano D; Musi G; de Cobelli O; Mirone V; Shariat SF
Clin Genitourin Cancer; 2018 Dec; 16(6):445-452. PubMed ID: 30077463
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of preoperative anemia on non-muscle-invasive bladder carcinoma treated with GreenLight laser vaporization.
Luo F; Wang YS; Su YH; Zhang ZH; Sun HH; Li J
Lasers Med Sci; 2017 Feb; 32(2):397-403. PubMed ID: 28013415
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Factors for Recurrence and Progression in Korean Non-Muscle-Invasive Bladder Cancer Patients: A Retrospective, Multi-Institutional Study.
Kim HS; Ku JH; Kim SJ; Hong SJ; Hong SH; Kim HS; Kwon TG; Cho JS; Jeon SS; Joo KJ; Ahn HJ; Park HS; Seong do H; Kwon DD; Kim HJ; Lim JS; Lee HL
Yonsei Med J; 2016 Jul; 57(4):855-64. PubMed ID: 27189277
[TBL] [Abstract][Full Text] [Related]
9. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer.
Quhal F; Pradere B; Laukhtina E; Sari Motlagh R; Mostafaei H; Mori K; Schuettfort VM; Karakiewicz PI; Rouprêt M; Enikeev D; Rink M; Abufaraj M; Shariat SF
World J Urol; 2021 Sep; 39(9):3345-3352. PubMed ID: 33496841
[TBL] [Abstract][Full Text] [Related]
11. The impact of preoperative anemia on oncologic outcome in patients undergoing radical cystectomy for urothelial carcinoma of the bladder.
Jo JK; Jeong SJ; Hong SK; Byun SS; Lee SE; Oh JJ
Int Urol Nephrol; 2016 Apr; 48(4):489-94. PubMed ID: 26810322
[TBL] [Abstract][Full Text] [Related]
12. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
13. Selection of adjuvant intravesical therapies using the European Organization for Research and Treatment of Cancer scoring system in patients at intermediate risk of non-muscle-invasive bladder cancer.
Ofude M; Kitagawa Y; Yaegashi H; Izumi K; Ueno S; Kadono Y; Konaka H; Mizokami A; Namiki M
J Cancer Res Clin Oncol; 2015 Jan; 141(1):161-8. PubMed ID: 25108407
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
15. Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C.
Xylinas E; Kent M; Dabi Y; Rieken M; Kluth LA; Al Hussein Al Awamlh B; Ouzaid I; Pycha A; Comploj E; Svatek RS; Lotan Y; Karakiewicz PI; Holmang S; Shariat SF
Urol Oncol; 2018 Mar; 36(3):89.e1-89.e5. PubMed ID: 29221642
[TBL] [Abstract][Full Text] [Related]
16. Impact of Bladder Neck Involvement on Recurrence in Patients With Non-muscle-invasive Bladder Cancer: An Analysis Based on a Time-dependent Model.
Waseda Y; Kobayashi S; Kanda E; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Fujii Y
Clin Genitourin Cancer; 2020 Apr; 18(2):e62-e70. PubMed ID: 31744700
[TBL] [Abstract][Full Text] [Related]
17. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111
[TBL] [Abstract][Full Text] [Related]
18. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer.
Mano R; Baniel J; Shoshany O; Margel D; Bar-On T; Nativ O; Rubinstein J; Halachmi S
Urol Oncol; 2015 Feb; 33(2):67.e1-7. PubMed ID: 25060672
[TBL] [Abstract][Full Text] [Related]
20. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre.
Ali-El-Dein B; Sooriakumaran P; Trinh QD; Barakat TS; Nabeeh A; Ibrahiem el-HI
BJU Int; 2013 Jun; 111(8):E331-41. PubMed ID: 23445082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
